WO2005034929A3 - Tissue remodeling and vascularization - Google Patents

Tissue remodeling and vascularization Download PDF

Info

Publication number
WO2005034929A3
WO2005034929A3 PCT/US2004/033706 US2004033706W WO2005034929A3 WO 2005034929 A3 WO2005034929 A3 WO 2005034929A3 US 2004033706 W US2004033706 W US 2004033706W WO 2005034929 A3 WO2005034929 A3 WO 2005034929A3
Authority
WO
WIPO (PCT)
Prior art keywords
vascularization
tissue remodeling
medicaments
therapeutic
compounds
Prior art date
Application number
PCT/US2004/033706
Other languages
French (fr)
Other versions
WO2005034929A2 (en
WO2005034929A9 (en
Inventor
Volkmar Guenzler-Pukall
Stephen J Klaus
Carl W White
Tiina Maria Asikainen
Original Assignee
Fibrogen Inc
Nat Jewish Med & Res Center
Volkmar Guenzler-Pukall
Stephen J Klaus
Carl W White
Tiina Maria Asikainen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc, Nat Jewish Med & Res Center, Volkmar Guenzler-Pukall, Stephen J Klaus, Carl W White, Tiina Maria Asikainen filed Critical Fibrogen Inc
Publication of WO2005034929A2 publication Critical patent/WO2005034929A2/en
Publication of WO2005034929A9 publication Critical patent/WO2005034929A9/en
Publication of WO2005034929A3 publication Critical patent/WO2005034929A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to methods, compounds, and medicaments for coordinate induction of tissue remodeling and vascularization, and for therapeutic or prophylactic treatment of disorders associated with vascular insufficiency.
PCT/US2004/033706 2003-10-10 2004-10-12 Tissue remodeling and vascularization WO2005034929A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51032303P 2003-10-10 2003-10-10
US60/510,323 2003-10-10

Publications (3)

Publication Number Publication Date
WO2005034929A2 WO2005034929A2 (en) 2005-04-21
WO2005034929A9 WO2005034929A9 (en) 2005-06-02
WO2005034929A3 true WO2005034929A3 (en) 2005-08-04

Family

ID=34435084

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/033706 WO2005034929A2 (en) 2003-10-10 2004-10-12 Tissue remodeling and vascularization

Country Status (1)

Country Link
WO (1) WO2005034929A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007101204A1 (en) * 2006-02-27 2007-09-07 Alcon Research, Ltd. Method of treating glaucoma
CN101415715B (en) * 2006-03-10 2012-10-10 住友化学株式会社 Fused ring compound and method for producing same, polymer, organic thin film containing those, and organic thin film device and organic thin film transistor comprising such organic thin film
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
CN109486745A (en) * 2017-09-12 2019-03-19 中国人民解放军第三军医大学第附属医院 Application of the FG-4592 in terms of promoting Migration of Epidermal Stem Cells
EP3768299A1 (en) 2018-03-22 2021-01-27 The Children's Medical Center Corporation Methods and compositions relating to lung repair
CA3177415A1 (en) * 2020-05-21 2021-11-25 Kevin Peters Methods of treating acute respiratory distress syndrome with activators of tie-2

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719164A (en) * 1995-09-28 1998-02-17 Hoechst Aktiengesellschaft Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates
WO2000074725A1 (en) * 1999-06-04 2000-12-14 Dana-Farber Cancer Institute, Inc. Identification of compounds that modify transcriptional responses to hypoxia
WO2002086497A2 (en) * 2001-04-24 2002-10-31 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of hypoxia inducible factor 2alpha for curing neonatal respiratory distress syndrome and as a target for the treatment of pulmonary hypertension
WO2003049686A2 (en) * 2001-12-06 2003-06-19 Fibrogen, Inc. Stabilization of hypoxia inducible factor (hif) alpha

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719164A (en) * 1995-09-28 1998-02-17 Hoechst Aktiengesellschaft Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates
WO2000074725A1 (en) * 1999-06-04 2000-12-14 Dana-Farber Cancer Institute, Inc. Identification of compounds that modify transcriptional responses to hypoxia
WO2002086497A2 (en) * 2001-04-24 2002-10-31 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of hypoxia inducible factor 2alpha for curing neonatal respiratory distress syndrome and as a target for the treatment of pulmonary hypertension
WO2003049686A2 (en) * 2001-12-06 2003-06-19 Fibrogen, Inc. Stabilization of hypoxia inducible factor (hif) alpha
US20030176317A1 (en) * 2001-12-06 2003-09-18 Volkmar Guenzler-Pukall Stabilization of hypoxia inducible factor (HIF) alpha

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
L'ALLEMAIN G: "LE FACTEUR DE L'HYPOXIE HIF: FUTURE CIBLE PHARMACOLOGIQUE THE HYPOXIA-INDUCIBLE FACTOR HIF AS A NEW TARGET IN CANCER RESEARCH", BULLETIN DU CANCER, EDITIONS SCIENTIFIQUES ELSEVIER, PARIS, FR, vol. 89, no. 3, March 2002 (2002-03-01), pages 257 - 260, XP009015502, ISSN: 0007-4551 *

Also Published As

Publication number Publication date
WO2005034929A2 (en) 2005-04-21
WO2005034929A9 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
TW200621765A (en) Substituted phenylaminothiazoles and their use
IL173123A0 (en) System and method for the photodynamic treatment of burns, wounds, and related skin disorders
AU2003286567A1 (en) Methods for the treatment of skin disorders
WO2003028802A3 (en) Devices for treating atrial fibrilation
IL184125A0 (en) Medicaments for the treatment or prevention of fibrotic diseases
AU2003300791A1 (en) Combination therapy for the treatment of pain
IL184124A0 (en) Medicaments for the treatment or prevention of fibrotic diseases
HK1093729A1 (en) Substituted quinolones
WO2003039539A3 (en) Use of endothelin receptor antagonists in the treatment of tumour diseases
WO2006089664A3 (en) Heterocyclylamide-substituted imidazoles
WO2008045378A3 (en) Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin
WO2004004653A3 (en) Methods for treating psychosis associated with interferon-alpha therapy
WO2005034929A3 (en) Tissue remodeling and vascularization
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
WO2006109170A3 (en) Combination therapy for treatment of cardiovascular diseases and related conditions
WO2000061231A3 (en) Medical use
AU2002365511A1 (en) Quinoline derivatives, process for preparing them and use for the treatment of diseases mediated by s-cd23
WO2005058290A3 (en) Vitamin e for facilitating the synchronization of circadian rhythm
MXPA04004763A (en) Double esters.
SI1474415T1 (en) 1-phenyl-2-heteroaryl-substituted benzimidazole derivatives, the use thereof for producing drugs used in the treatment of immunological diseases
WO2009024325A3 (en) Treatment of sleep disorders
WO2005097138A3 (en) Combinations comprising oxcarbazepine to treat affective disorders
ZA200308216B (en) Medicament for the treatment of immuno-deficiency conditions.
AU2002365654A1 (en) Treatment of diseases via the skin
ITBO20030101A1 (en) METHOD FOR THE AESTHETIC TREATMENT OF PORTIONS OF THE HUMAN BODY.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1, 2, 15, 20, 24, 25 DESCRIPTION, REPLACED BY NEW PAGES 1, 2, 15, 20, 24, 25, PAGES 2/5, 3/5 DRAWINGS REPLACED BY NEW PAGES 2/5, 3/5; AFTER RECTIFICATION OF OBVIOUS ERRORS AUTHORIZED BY THE INTERNATIONAL SEARCH AUTHORITY

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase